Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while market based multiples lean expensive and the broader checks do not suggest a clear bargain.
Tempus AI has returned about 54.8% over the past month, which puts extra focus on whether that jump is already pricing in much of the good news.
The positive cancer vaccine trial linked to its planned US$1.5b Personalis acquisition can support higher growth expectations, but execution risk around integrating Personalis and converting that clinical momentum into durable cash flows may weigh on valuation.
The stock only clears 2 of 6 valuation checks, which means that on Simply Wall St’s broader framework it leans expensive rather than screening as a straightforward bargain 2.
The issue now is whether Tempus AI’s recent rally leaves enough margin between the market price and intrinsic value estimate to compensate for the risks in front of it.
Find out why Tempus AI’s -9.7% return over the last year is lagging behind its peers.
Does Tempus AI Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Tempus AI could be worth based on its future cash flows rather than current earnings multiples. Tempus AI reported latest twelve month free cash flow of about $274.1 million in outflows, so the model assumes the business moves from cash burn toward growing positive cash generation over time. On that basis, the DCF points to an intrinsic value of about $109 per share.
This sits above the current share price and implies the stock trades at roughly a 33.1% discount to the modelled value. The positive Merck and Moderna cancer vaccine trial that supports the planned Personalis acquisition helps explain why the market is now assigning more value to Tempus AI’s future cash flows, and the DCF still suggests further upside based purely on those projected cash flows.
On balance, the DCF workup indicates Tempus AI stock currently looks undervalued relative to its projected cash flow profile.
Our Discounted Cash Flow (DCF) analysis suggests Tempus AI is undervalued by 33.1%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.
TEM Discounted Cash Flow as at Aug 2026
Story Continues
Has Tempus AI Run Too Far on Sales?
P/S is a useful lens for Tempus AI because revenue is a more stable anchor than earnings while the business is still investing heavily and reporting losses.
Tempus AI trades on a P/S of about 9.2x, which is well above the Life Sciences industry average of roughly 4.6x. It also sits higher than the peer group average of about 6.0x, so the stock already carries a clear premium to both its sector and more direct comparables on this metric.
Simply Wall St’s fair P/S ratio for Tempus AI is estimated at around 8.2x, based on its revenue profile, size and risk factors. The current 9.2x level is above that fair ratio, which implies the recent share price strength leaves the stock screening as overvalued on sales relative to what this framework suggests is reasonable.
On this P/S framework, Tempus AI stock currently screens as overvalued compared with both its industry and its modelled fair multiple.
NasdaqGS:TEM P/S Ratio as at Aug 2026
See what the numbers say about this price — find out in our valuation breakdown.
The Tempus AI Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives take this valuation puzzle for Tempus AI and explain which assumptions on future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today, based on scenarios discussed on the Community page. Each narrative links a fair value view to a specific mix of potential catalysts and risks so you can track over time which version of Tempus AI’s story is actually unfolding.
Community views on Tempus AI are split between those who see a data platform with room to rerate and those who think expectations already stretch the story.
Bull case: 24% undervalued
“Development of large scale multimodal foundation models with AstraZeneca and Pathos, combined with Paige’s digital pathology capabilities and Tempus AI’s AI algorithms across multiple specialties, can expand high margin software and algorithmic offerings that help earnings mix over time…”
Read the full Bull Case to see why Tempus AI could be undervalued
Bear case: 10% overvalued
“Tempus has accumulated tens of millions of de-identified patient records and hundreds of petabytes of clinical and molecular data, assets that would take competitors years and enormous investment to replicate…”
Read the full Bear Case to see why Tempus AI could be overvalued
Do you think there’s more to the story for Tempus AI? Head over to our Community to see what others are saying!
The Bottom Line
Tempus AI offers a mixed picture. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside relative to the current share price, yet market based multiples flag the stock as overvalued on sales compared with peers. The broader valuation checks are weak, which tempers the single undervalued signal from the DCF work. The key question now is whether Tempus AI can turn its data assets and recent clinical momentum into durable, high quality cash flows without integration or execution issues eroding that apparent discount.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TEM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com